Teachers Advisors’s Viridian Therapeutics VRDN Stock Holding History

Teachers Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$93K	Hold	2,223	–	–	﹤0.01%	2941
2018 Q4	$101K	Hold	2,223	–	–	﹤0.01%	2950
2018 Q3	$186K	Sell	2,223 -16	-0.7%	-$1.51K	﹤0.01%	2955
2018 Q2	$215K	Buy	2,239 +693	+45%	+$73.3K	﹤0.01%	2973
2018 Q1	$163K	Hold	1,546	–	–	﹤0.01%	2913
2017 Q4	$242K	Hold	1,546	–	–	﹤0.01%	2882
2017 Q3	$212K	Sell	1,546 -116	-7%	-$19.5K	﹤0.01%	2955
2017 Q2	$322K	Buy	+1,662	New	+$281K	﹤0.01%	2819

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Teachers Advisors's VRDN Position: Q1 2019 in Review

Teachers Advisors held its Viridian Therapeutics (VRDN) position steady in Q1 2019 at 2,223 shares worth $93K. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

Teachers Advisors first reported a position in VRDN in Q2 2017 and has held it in 8 quarters since. The position peaked at $322K in Q2 2017. 51 funds tracked by Wall St. Rank hold VRDN as of Q1 2019.

Teachers Advisors held 2,223 shares of Viridian Therapeutics worth $93K as of Q1 2019.
Teachers Advisors left its Viridian Therapeutics share count unchanged in Q1 2019.
Viridian Therapeutics made up ﹤0.01% of Teachers Advisors's portfolio in Q1 2019, its #2941 holding.
Teachers Advisors first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 8 quarters since.
Teachers Advisors's Viridian Therapeutics position peaked at $322K in Q2 2017.
51 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2019.

Based on Teachers Advisors's 13F filing for Q1 2019, filed 14 May 2019.